Evidence map›Paper›PMID 40899880›Full record

ArticleMicrobiology spectrum2025

Application of engineered CRISPR/Cas12a variants with altered protospacer adjacent motif specificities for the detection of isoniazid resistance mutations in

Peng Liu, Jinping Zhang, Yaqi Gong, Wenqi Liu, Guohui Xiao, Juan Liang, Xuan Wang, Jing Bi, Guoliang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Anti-TB Drugs for Drug-Sensitive and Drug-ResistantCurrent issues in molecular biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peng Liu *National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Jinping Zhang *Wuhan Pulmonary Hospital, Wuhan Tuberculosis Prevention and Control Institute, The Hubei Branch of the National Clinical Research Center for Infectious Disease, Wuhan, China.
Yaqi Gong *National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Wenqi LiuNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Guohui XiaoNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID 0000-0002-0298-6710
Juan LiangClinical Laboratory Experiment Center, Hangzhou Red Cross Hospital, Zhejiang, China.
Xuan WangWuhan Pulmonary Hospital, Wuhan Tuberculosis Prevention and Control Institute, The Hubei Branch of the National Clinical Research Center for Infectious Disease, Wuhan, China.
Jing BiNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Guoliang ZhangNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID 0000-0002-3617-5449

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant tuberculosis (TB) is a major global public health concern. Although isoniazid is currently considered one of the most effective first-line drugs for TB treatment, its efficacy is limited by the emergence of resistance. Therefore, it is imperative to develop new methods for detecting drug-resistant TB. In this study, we developed a nucleic acid detection system based on the clustered regularly interspaced short palindromic repeat (CRISPR) Cas12a_RR protein. The system combines recombinase polymerase amplification with an engineered CRISPR/Cas12a_RR protein to enable rapid and specific detection of the IMPORTANCE: This study presents a novel method for detecting isoniazid-resistant

Indexed as

Antitubercular AgentsCRISPR-Cas SystemsDrug Resistance, BacterialEndodeoxyribonucleasesIsoniazidMycobacterium tuberculosisBacterial ProteinsCatalaseClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Associated ProteinsHumansMicrobial Sensitivity TestsMutationSensitivity and SpecificityTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsCas12a proteinCatalaseCRISPR-Associated ProteinsEndodeoxyribonucleasesIsoniazidkatG protein, Mycobacterium tuberculosisCas12a_RRclustered regularly interspaced short palindromic repeatsdrug-resistantisoniazidtuberculosis

Identifiers

PMID40899880
PMCPMC12502725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.